nodes	percent_of_prediction	percent_of_DWPC	metapath
Methyclothiazide—Gastric irritation—Hydroxyurea—head and neck cancer	0.0903	0.0922	CcSEcCtD
Methyclothiazide—Epigastric discomfort—Hydroxyurea—head and neck cancer	0.0666	0.068	CcSEcCtD
Methyclothiazide—Hyperuricaemia—Hydroxyurea—head and neck cancer	0.0377	0.0385	CcSEcCtD
Methyclothiazide—Blood uric acid increased—Hydroxyurea—head and neck cancer	0.0356	0.0364	CcSEcCtD
Methyclothiazide—Pulmonary oedema—Hydroxyurea—head and neck cancer	0.0312	0.0318	CcSEcCtD
Methyclothiazide—Pancreatitis—Hydroxyurea—head and neck cancer	0.0215	0.022	CcSEcCtD
Methyclothiazide—Photosensitivity—Fluorouracil—head and neck cancer	0.0208	0.0213	CcSEcCtD
Methyclothiazide—Agranulocytosis—Vinblastine—head and neck cancer	0.02	0.0205	CcSEcCtD
Methyclothiazide—Pulmonary oedema—Docetaxel—head and neck cancer	0.0162	0.0165	CcSEcCtD
Methyclothiazide—Vertigo—Vinblastine—head and neck cancer	0.0151	0.0154	CcSEcCtD
Methyclothiazide—Leukopenia—Vinblastine—head and neck cancer	0.015	0.0153	CcSEcCtD
Methyclothiazide—Photosensitivity reaction—Fluorouracil—head and neck cancer	0.0144	0.0147	CcSEcCtD
Methyclothiazide—Pneumonia—Fluorouracil—head and neck cancer	0.0142	0.0145	CcSEcCtD
Methyclothiazide—Leukopenia—Hydroxyurea—head and neck cancer	0.0137	0.014	CcSEcCtD
Methyclothiazide—Thrombocytopenia—Vinblastine—head and neck cancer	0.0134	0.0137	CcSEcCtD
Methyclothiazide—Agranulocytosis—Fluorouracil—head and neck cancer	0.0132	0.0134	CcSEcCtD
Methyclothiazide—Anorexia—Vinblastine—head and neck cancer	0.0131	0.0133	CcSEcCtD
Methyclothiazide—Paraesthesia—Vinblastine—head and neck cancer	0.0123	0.0126	CcSEcCtD
Methyclothiazide—Thrombocytopenia—Hydroxyurea—head and neck cancer	0.0122	0.0125	CcSEcCtD
Methyclothiazide—Orthostatic hypotension—Docetaxel—head and neck cancer	0.0121	0.0123	CcSEcCtD
Methyclothiazide—Anorexia—Hydroxyurea—head and neck cancer	0.0119	0.0122	CcSEcCtD
Methyclothiazide—Decreased appetite—Vinblastine—head and neck cancer	0.0119	0.0122	CcSEcCtD
Methyclothiazide—Cramp muscle—Docetaxel—head and neck cancer	0.0119	0.0121	CcSEcCtD
Methyclothiazide—Constipation—Vinblastine—head and neck cancer	0.0117	0.012	CcSEcCtD
Methyclothiazide—Decreased appetite—Hydroxyurea—head and neck cancer	0.0109	0.0111	CcSEcCtD
Methyclothiazide—Constipation—Hydroxyurea—head and neck cancer	0.0107	0.0109	CcSEcCtD
Methyclothiazide—Vision blurred—Fluorouracil—head and neck cancer	0.0104	0.0106	CcSEcCtD
Methyclothiazide—Pneumonia—Docetaxel—head and neck cancer	0.0102	0.0104	CcSEcCtD
Methyclothiazide—Hypersensitivity—Vinblastine—head and neck cancer	0.0101	0.0103	CcSEcCtD
Methyclothiazide—Stevens-Johnson syndrome—Docetaxel—head and neck cancer	0.0101	0.0103	CcSEcCtD
Methyclothiazide—Jaundice—Docetaxel—head and neck cancer	0.00992	0.0101	CcSEcCtD
Methyclothiazide—Body temperature increased—Hydroxyurea—head and neck cancer	0.00987	0.0101	CcSEcCtD
Methyclothiazide—Leukopenia—Fluorouracil—head and neck cancer	0.00986	0.0101	CcSEcCtD
Methyclothiazide—Asthenia—Vinblastine—head and neck cancer	0.00983	0.01	CcSEcCtD
Methyclothiazide—Agranulocytosis—Docetaxel—head and neck cancer	0.00949	0.0097	CcSEcCtD
Methyclothiazide—Diarrhoea—Vinblastine—head and neck cancer	0.00937	0.00957	CcSEcCtD
Methyclothiazide—Hypersensitivity—Hydroxyurea—head and neck cancer	0.0092	0.0094	CcSEcCtD
Methyclothiazide—Dizziness—Vinblastine—head and neck cancer	0.00906	0.00925	CcSEcCtD
Methyclothiazide—Anaphylactic shock—Fluorouracil—head and neck cancer	0.00899	0.00918	CcSEcCtD
Methyclothiazide—Asthenia—Hydroxyurea—head and neck cancer	0.00896	0.00915	CcSEcCtD
Methyclothiazide—Thrombocytopenia—Fluorouracil—head and neck cancer	0.0088	0.00899	CcSEcCtD
Methyclothiazide—Vomiting—Vinblastine—head and neck cancer	0.00871	0.00889	CcSEcCtD
Methyclothiazide—Erythema multiforme—Docetaxel—head and neck cancer	0.00863	0.00882	CcSEcCtD
Methyclothiazide—Headache—Vinblastine—head and neck cancer	0.00858	0.00876	CcSEcCtD
Methyclothiazide—Anorexia—Fluorouracil—head and neck cancer	0.00857	0.00875	CcSEcCtD
Methyclothiazide—Diarrhoea—Hydroxyurea—head and neck cancer	0.00854	0.00873	CcSEcCtD
Methyclothiazide—Dizziness—Hydroxyurea—head and neck cancer	0.00826	0.00843	CcSEcCtD
Methyclothiazide—Nausea—Vinblastine—head and neck cancer	0.00813	0.00831	CcSEcCtD
Methyclothiazide—Paraesthesia—Fluorouracil—head and neck cancer	0.00807	0.00824	CcSEcCtD
Methyclothiazide—Malnutrition—Docetaxel—head and neck cancer	0.00795	0.00812	CcSEcCtD
Methyclothiazide—Vomiting—Hydroxyurea—head and neck cancer	0.00794	0.00811	CcSEcCtD
Methyclothiazide—Rash—Hydroxyurea—head and neck cancer	0.00787	0.00804	CcSEcCtD
Methyclothiazide—Dermatitis—Hydroxyurea—head and neck cancer	0.00787	0.00803	CcSEcCtD
Methyclothiazide—Headache—Hydroxyurea—head and neck cancer	0.00782	0.00799	CcSEcCtD
Methyclothiazide—Decreased appetite—Fluorouracil—head and neck cancer	0.00781	0.00798	CcSEcCtD
Methyclothiazide—Muscle spasms—Docetaxel—head and neck cancer	0.00764	0.00781	CcSEcCtD
Methyclothiazide—Nausea—Hydroxyurea—head and neck cancer	0.00742	0.00758	CcSEcCtD
Methyclothiazide—Urticaria—Fluorouracil—head and neck cancer	0.00714	0.00729	CcSEcCtD
Methyclothiazide—Leukopenia—Docetaxel—head and neck cancer	0.00712	0.00727	CcSEcCtD
Methyclothiazide—Body temperature increased—Fluorouracil—head and neck cancer	0.00711	0.00726	CcSEcCtD
Methyclothiazide—Hypersensitivity—Fluorouracil—head and neck cancer	0.00662	0.00676	CcSEcCtD
Methyclothiazide—Anaphylactic shock—Docetaxel—head and neck cancer	0.00649	0.00663	CcSEcCtD
Methyclothiazide—Thrombocytopenia—Docetaxel—head and neck cancer	0.00635	0.00649	CcSEcCtD
Methyclothiazide—Anorexia—Docetaxel—head and neck cancer	0.00618	0.00632	CcSEcCtD
Methyclothiazide—Diarrhoea—Fluorouracil—head and neck cancer	0.00615	0.00628	CcSEcCtD
Methyclothiazide—Dizziness—Fluorouracil—head and neck cancer	0.00594	0.00607	CcSEcCtD
Methyclothiazide—Paraesthesia—Docetaxel—head and neck cancer	0.00583	0.00595	CcSEcCtD
Methyclothiazide—Vomiting—Fluorouracil—head and neck cancer	0.00572	0.00584	CcSEcCtD
Methyclothiazide—Rash—Fluorouracil—head and neck cancer	0.00567	0.00579	CcSEcCtD
Methyclothiazide—Dermatitis—Fluorouracil—head and neck cancer	0.00566	0.00578	CcSEcCtD
Methyclothiazide—Decreased appetite—Docetaxel—head and neck cancer	0.00564	0.00576	CcSEcCtD
Methyclothiazide—Headache—Fluorouracil—head and neck cancer	0.00563	0.00575	CcSEcCtD
Methyclothiazide—Constipation—Docetaxel—head and neck cancer	0.00555	0.00567	CcSEcCtD
Methyclothiazide—Nausea—Fluorouracil—head and neck cancer	0.00534	0.00545	CcSEcCtD
Methyclothiazide—Body temperature increased—Docetaxel—head and neck cancer	0.00513	0.00524	CcSEcCtD
Methyclothiazide—Hypersensitivity—Docetaxel—head and neck cancer	0.00478	0.00488	CcSEcCtD
Methyclothiazide—Asthenia—Docetaxel—head and neck cancer	0.00466	0.00475	CcSEcCtD
Methyclothiazide—Diarrhoea—Docetaxel—head and neck cancer	0.00444	0.00453	CcSEcCtD
Methyclothiazide—Dizziness—Docetaxel—head and neck cancer	0.00429	0.00438	CcSEcCtD
Methyclothiazide—Vomiting—Docetaxel—head and neck cancer	0.00413	0.00421	CcSEcCtD
Methyclothiazide—Rash—Docetaxel—head and neck cancer	0.00409	0.00418	CcSEcCtD
Methyclothiazide—Dermatitis—Docetaxel—head and neck cancer	0.00409	0.00417	CcSEcCtD
Methyclothiazide—Headache—Docetaxel—head and neck cancer	0.00406	0.00415	CcSEcCtD
Methyclothiazide—Nausea—Docetaxel—head and neck cancer	0.00385	0.00394	CcSEcCtD
Methyclothiazide—CA2—exocrine gland—head and neck cancer	0.00161	0.0773	CbGeAlD
Methyclothiazide—SLC12A1—epithelium—head and neck cancer	0.00157	0.0754	CbGeAlD
Methyclothiazide—CA2—hair follicle—head and neck cancer	0.00153	0.0737	CbGeAlD
Methyclothiazide—CA4—neck—head and neck cancer	0.00124	0.0596	CbGeAlD
Methyclothiazide—CA2—mouth—head and neck cancer	0.0012	0.0578	CbGeAlD
Methyclothiazide—CA2—neck—head and neck cancer	0.00103	0.0495	CbGeAlD
Methyclothiazide—CA4—parotid gland—head and neck cancer	0.00101	0.0486	CbGeAlD
Methyclothiazide—SLC12A1—head—head and neck cancer	0.000974	0.0468	CbGeAlD
Methyclothiazide—CA4—saliva-secreting gland—head and neck cancer	0.000968	0.0465	CbGeAlD
Methyclothiazide—CA2—parotid gland—head and neck cancer	0.000838	0.0403	CbGeAlD
Methyclothiazide—CA1—lymphoid tissue—head and neck cancer	0.000832	0.04	CbGeAlD
Methyclothiazide—CA2—saliva-secreting gland—head and neck cancer	0.000802	0.0386	CbGeAlD
Methyclothiazide—CA4—trachea—head and neck cancer	0.000746	0.0359	CbGeAlD
Methyclothiazide—CA2—connective tissue—head and neck cancer	0.000737	0.0354	CbGeAlD
Methyclothiazide—CA2—epithelium—head and neck cancer	0.0007	0.0336	CbGeAlD
Methyclothiazide—CA1—head—head and neck cancer	0.00067	0.0322	CbGeAlD
Methyclothiazide—CA2—trachea—head and neck cancer	0.000619	0.0298	CbGeAlD
Methyclothiazide—CA4—thyroid gland—head and neck cancer	0.00059	0.0284	CbGeAlD
Methyclothiazide—CA2—lymphoid tissue—head and neck cancer	0.000539	0.0259	CbGeAlD
Methyclothiazide—CA4—head—head and neck cancer	0.000524	0.0252	CbGeAlD
Methyclothiazide—CA2—thyroid gland—head and neck cancer	0.00049	0.0235	CbGeAlD
Methyclothiazide—CA1—lymph node—head and neck cancer	0.000469	0.0226	CbGeAlD
Methyclothiazide—CA2—head—head and neck cancer	0.000434	0.0209	CbGeAlD
Methyclothiazide—CA4—lymph node—head and neck cancer	0.000367	0.0176	CbGeAlD
Methyclothiazide—CA2—lymph node—head and neck cancer	0.000304	0.0146	CbGeAlD
